Pasireotide

Generic Name: Pasireotide

Brand Names: Signifor

Drug Type: Small Molecule

Chemical Formula: C_₅₈H_₆₆N_₁₀O_₉

CAS Number: 396091-73-9

Unique Ingredient Identifier: 98H1T17066

Background: Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.

Indication: For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.

Associated Conditions: Acromegaly, Cushing's Disease

Clinical Trials

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Phase 2

Terminated

Conditions: Pancreatic Neoplasm
Pituitary Neoplasm
Nelson Syndrome
Ectopic ACTH Syndrome

Interventions: Drug: pasireotide LAR

First Posted Date: 2009-08-13

Last Posted Date: 2016-07-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 118

Registration Number: NCT00958841

Locations: 🇺🇸
Cedars Sinai Medical Center The Pituitary Center (3), Los Angeles, California, United States
🇺🇸
Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles, California, United States
🇺🇸
Mount Sinai School of Medicine Study Coordinator, New York, New York, United States

and more 4 locations

Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas

Phase 2

Terminated

Conditions: Gonadotroph Adenomas

Interventions: Drug: pasireotide LAR

First Posted Date: 2009-06-29

Last Posted Date: 2017-11-28

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 2

Registration Number: NCT00929669

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Phase 1

Completed

Conditions: Neuroendocrine Tumor
Carcinoid Tumor
Pancreatic Neuroendocrine Tumor

Interventions: Drug: SOM230
Drug: RAD001

First Posted Date: 2008-12-08

Last Posted Date: 2016-10-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 22

Registration Number: NCT00804336

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function

Phase 1

Completed

Conditions: Alcoholism
Hepatic Cirrhosis

Interventions: Drug: Pasireotide

First Posted Date: 2008-06-17

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 34

Registration Number: NCT00698464

Locations: 🇩🇪
Novartis Investigative site, Berlin, Germany
🇿🇦
Novartis Investigative Site, George, South Africa
🇧🇪
Universite Catholique de Louvain, Brussels, Belgium

and more 1 locations

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Phase 3

Completed

Conditions: Symptomatic Refractory Resistant Carcinoid Disease

Interventions: Drug: Pasireotide
Drug: Octreotide

First Posted Date: 2008-06-04

Last Posted Date: 2013-07-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 186

Registration Number: NCT00690430

Locations: 🇺🇸
University of Arizona / Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Scottsdale Healthcare/TGen Clinical Research Service TGen Clinical Research Service, Scottsdale, Arizona, United States
🇺🇸
Loma Linda University Dept. of Loma Linda CancerCent, Loma Linda, California, United States

and more 8 locations

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

Phase 3

Completed

Conditions: Acromegaly

Interventions: Drug: Pasireotide
Drug: Octreotide

First Posted Date: 2008-01-25

Last Posted Date: 2017-07-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 358

Registration Number: NCT00600886

Locations: 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom
🇺🇸
Johns Hopkins University School of Medicine Dept.ofJohnsHopkinsUniv., Baltimore, Maryland, United States
🇺🇸
University of Michigan Comprehensive Cancer Center Deptof Endocrinology&Diabetes, Ann Arbor, Michigan, United States

and more 12 locations

Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

Phase 1

Completed

Conditions: Acromegaly
Carcinoid Tumor

Interventions: Drug: Pasireotide

First Posted Date: 2007-03-12

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 85

Registration Number: NCT00446082

Locations: 🇳🇴
Novartis Investigative Site, Oslo, Norway
🇺🇸
Cedars Sinai Medical Center SC - 4, Los Angeles, California, United States
🇺🇸
Stanford University Medical Center Stanford Cancer Center (3), Stanford, California, United States

and more 2 locations

Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease

Phase 3

Completed

Conditions: Cushing's Disease

Interventions: Drug: Pasireotide

First Posted Date: 2007-02-12

Last Posted Date: 2016-03-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 162

Registration Number: NCT00434148

Locations: 🇹🇷
Novartis Investigative Site, Fatih / Istanbul, Turkey
🇺🇸
Stanford University Medical Center Stanford Cancer Center (3), Stanford, California, United States
🇺🇸
University Chicago Hospital Dept. of Univ of Chicago, Chicago, Illinois, United States

and more 8 locations

An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly

Phase 2

Completed

Conditions: Acromegaly

Interventions: Drug: Pasireotide

First Posted Date: 2005-09-15

Last Posted Date: 2021-09-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT00171730

Locations: 🇺🇸
NYU / VA Medical Center, New York, New York, United States
🇨🇭
Novartis Investigative Site, Lausanne, Switzerland
🇺🇸
Cedars Sinai Medical Center Dept. of Pituitary Ctr., Los Angeles, California, United States

and more 1 locations

Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease

Phase 2

Completed

Conditions: Cushing Disease

Interventions: Drug: Pasireotide

First Posted Date: 2005-09-15

Last Posted Date: 2021-06-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 19

Registration Number: NCT00171951

Locations: 🇬🇧
Novartis Investigative Site, Belfast, United Kingdom
🇺🇸
Oregon Health & Sciences University Dept.ofOregonHealth&SciencesU., Portland, Oregon, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy